HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Genetic heterogeneity among visceral and post-Kala-Azar dermal leishmaniasis strains from eastern India.

Abstract
In India and Sudan, some patients of visceral leishmaniasis develop post-Kala-Azar dermal leishmaniasis (PKDL) while majority will not. Similarly, the clinical manifestations and treatment outcome are reported to vary from district to district and state to state in India. Present study is focused on to find out the genetic variations between VL & PKDL causing strains. Nuclear DNA from 24 strains of Leishmania donovani, isolated from patients of visceral leishmaniasis (18) and PKDL (6) was extracted and digested with PstI restriction enzyme followed by southern hybridization using Dig labeled beta-tubulin as probe. The results showed three different banding patterns among 18 VL strains. However, all PKDL isolates showed a genetic homogeneity within themselves but heterogeneity from VL isolates. Interestingly maximum heterogenic groups were found in Bihar but all isolates from West Bengal showed a single genotype origin. This study shows that genetic mutations might be responsible for such variation and development of PKDL in visceral strains of Indian L. donovani.
AuthorsAyan Dey, Sarman Singh
JournalInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases (Infect Genet Evol) Vol. 7 Issue 2 Pg. 219-22 (Mar 2007) ISSN: 1567-1348 [Print] Netherlands
PMID17027344 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • DNA, Protozoan
  • Tubulin
Topics
  • Animals
  • DNA, Protozoan (genetics)
  • Genetic Heterogeneity
  • Genetic Variation
  • Genotype
  • Humans
  • India
  • Leishmania donovani (genetics, isolation & purification)
  • Leishmaniasis, Cutaneous (parasitology)
  • Leishmaniasis, Visceral (parasitology)
  • Tubulin (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: